| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by first author.
Page 9: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 2401 | 6 | 18 | 812 1983 BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE 96(7):910-913 VAISMAN BL; POPOV VP; IGNATEVA TV REDUCTION IN THE TISSUE ASCORBIC-ACID LEVEL IN GUINEA-PIGS BY THALIDOMIDE | 1 | 2 |
| 2402 | 1 | 5 | 2329 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(6):286-286 Valero FC Lung toxicity due to thalidomide | 0 | 0 |
| 2403 | 18 | 27 | 2037 2002 ARCHIVOS DE BRONCONEUMOLOGIA 38(10):492-494 Valero FC; Gonzalez VB Lung toxicity due to thalidomide | 1 | 1 |
| 2404 | 6 | 16 | 1689 2000 CANCER PRACTICE 8(2):101-103 Valorie AM Thalidomide - A new beginning | 0 | 1 |
| 2405 | 7 | 20 | 1709 2000 EUROPEAN CYTOKINE NETWORK 11(4):574-579 van Crevel R; Vonk AG; Netea MG; Kullberg BJ; van der Meer JWM Modulation of LPS-, PHA-and M-tuberculosis-mediated cytokine production by pentoxifylline and thalidomide | 2 | 3 |
| 2406 | 13 | 21 | 1982 2001 NETHERLANDS JOURNAL OF MEDICINE 59(2):45-49 van de Poel MHW; Pasman PC; Schouten HC The use of thalidomide in chronic refractory graft versus host disease | 1 | 3 |
| 2407 | 0 | 1 | 407 1966 NEW REPUBLIC 154(8):36-37 VANAALST FL THALIDOMIDE | 0 | 0 |
| 2408 | 0 | 0 | 1311 1997 ANNALS OF INTERNAL MEDICINE 127(10):951-952 Vanchieri C Preparing for thalidomide's comeback | 1 | 1 |
| 2409 | 7 | 10 | 720 1980 ARCHIVES OF DERMATOLOGY 116(5):571-572 VANDENBROEK H TREATMENT OF PRURIGO NODULARIS WITH THALIDOMIDE | 35 | 48 |
| 2410 | 0 | 16 | 783 1982 EUROPEAN JOURNAL OF PEDIATRICS 138(1):77-80 VANREGEMORTER N; HAUMONT D; KIRKPATRICK C; VISEUR P; JEANTY P; DODION J; MILAIRE J; ROOZE M; RODESCH F HOLT ORAM SYNDROME MISTAKEN FOR THALIDOMIDE EMBRYOPATHY - EMBRYOLOGICAL CONSIDERATIONS | 1 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2411 | 0 | 1 | 191 1963 BIOCHEMICAL PHARMACOLOGY 12:246-& VASILESCU V; CIURES A; DIMOFTAC.C; TRUTIA E DES RESULTATS CONCERNANT LACTION DE LA THALIDOMIDE SUR LES ACIDES NUCLEIQUES | 0 | 0 |
| 2412 | 0 | 14 | 294 1964 NATURE 202(493):1080-& VASILESCU V; CONSTANTINESCU M; DIMOFTAC.C; CIURES A CYTOSPECTROPHOTOMETRIC INVESTIGATION OF ACTION OF THALIDOMIDE ON NUCLEUS OF LYMPHOCYTE | 0 | 6 |
| 2413 | 19 | 40 | 1544 1999 GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
| 2414 | 0 | 0 | 1541 1999 GASTROENTEROLOGY 116(4):A837-A837 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Papadakis KA; Zeldis JB; Targan SR An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD) | 3 | 0 |
| 2415 | 0 | 0 | 2332 2003 ARTHRITIS AND RHEUMATISM 48(9):S588-S589 Vazquez-Cobian LB; Onel KB; Lehman TJA Thalidomide in systemic lupus erythematosus. | 0 | 0 |
| 2416 | 0 | 0 | 1729 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S180-S180 Velez G; King BA; Yuan P; Whitcup SM; Robison MR Thalidomide analogue (EM-138) sustained release implants to treat choroidal neovascularization associated with macular degeneration | 0 | 0 |
| 2417 | 0 | 0 | 1555 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S84-S84 Velez G; Robinson MR; Durbin T; Yuan P; Sung C; Whitcup SM Thalidomide-sustained release devices for choroidal neovascularization; An in-vitro analysis | 0 | 1 |
| 2418 | 0 | 0 | 773 1982 ANNALES DE PEDIATRIE 29(1):67-69 VENENCIE PY; SAURAT JH PYODERMA GANGRENOSUM IN A CHILD - TREATMENT WITH THALIDOMIDE | 20 | 36 |
| 2419 | 0 | 20 | 807 1983 BRITISH MEDICAL JOURNAL 286(6360):199-202 VENNING GR IDENTIFICATION OF ADVERSE REACTIONS TO NEW DRUGS .1. WHAT HAVE BEEN THE IMPORTANT ADVERSE REACTIONS SINCE THALIDOMIDE | 0 | 59 |
| 2420 | 0 | 0 | 1643 2000 BLOOD 96(11):232B-232B Venugopal P; Sivaraman S; Gladstone B; Jajeh A; Huang XK; Brien TO; ODonnell K; Gregory S; Preisler H Thalidomide (T) influences antigen expression on tumor cells from chronic lymphocytic leukemia. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2421 | 0 | 0 | 2166 2002 CLINICAL IMMUNOLOGY 103(3):S95-S95 Verastegui E; Morales R; Martinez R; Barrera J Immunological effects of thalidomide treatment of cancer patients. | 0 | 0 |
| 2422 | 2 | 5 | 1283 1996 LANCET 347(9006):974-974 Verberkmoes A; Boer K; Wertheim PME; Bronkhorst CM; Lange JMA Thalidomide for genital ulcer in HIV-positive woman | 4 | 9 |
| 2423 | 17 | 32 | 1623 2000 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 16 | 17 |
| 2424 | 7 | 42 | 1521 1999 BRITISH JOURNAL OF CANCER 79(1):114-118 Verheul HMW; Panigrahy D; Yuan J; D'Amato RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits | 16 | 31 |
| 2425 | 0 | 0 | 1658 2000 BLOOD 96(11):296B-296B Vescio RA; Berenson JR Thalidomide is an effective agent for patients with primary amyloidosis. | 0 | 1 |
| 2426 | 0 | 0 | 1710 2000 EUROPEAN HEART JOURNAL 21:367-367 Vescovo G; Ceconi C; Ferrari R; Ambrosio GB; Ravara B; Angelini A; Corti A; Rossini K; Sandri M; Leprotti C; Dalla Libera L Does thalidomide block apoptosis and prevent from the development of skeletal muscle myopathy in chronic heart failure? | 0 | 0 |
| 2427 | 5 | 25 | 2180 2002 EUROPEAN JOURNAL OF HEART FAILURE 4(4):455-460 Vescovo G; Ravara B; Angelini A; Sandri M; Carraro U; Ceconi C; Libera LD Effect of thalidomide on the skeletal muscle in experimental heart failure | 1 | 2 |
| 2428 | 1 | 6 | 2454 2003 EUROPEAN JOURNAL OF HAEMATOLOGY 70(3):198-199 Vicari P; Ribas C; Sampaio M; Arantes AM; Yamamoto M; Reis JB; Segreto RA; Bordin JO; Colleoni GWB Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? | 0 | 0 |
| 2429 | 7 | 10 | 1086 1993 ARCHIVES OF INTERNAL MEDICINE 153(4):534-534 VICENTE T; ORTEGA A; MUNOZ P; DIAZ MD; BOUZA E INVITRO ACTIVITY OF THALIDOMIDE AGAINST MYCOBACTERIUM-AVIUM COMPLEX | 5 | 6 |
| 2430 | 0 | 0 | 159 1962 MEDICAL JOURNAL OF AUSTRALIA 1(17):649-& VICKERS TH CONGENITAL ABNORMALITIES AND THALIDOMIDE | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2431 | 2 | 7 | 425 1967 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 48(1):107-& VICKERS TH THALIDOMIDE EMBRYOPATHY IN HYBRID RABBITS | 8 | 20 |
| 2432 | 5 | 8 | 427 1967 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 48(6):579-& VICKERS TH CONCERNING MORPHOGENESIS OF THALIDOMIDE DYSMELIA IN RABBITS | 12 | 18 |
| 2433 | 3 | 8 | 452 1968 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 49(2):179-& VICKERS TH CARDIOVASCULAR MALFORMATIONS IN RABBIT THALIDOMIDE EMBRYOPATHY | 2 | 5 |
| 2434 | 7 | 20 | 498 1970 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 51(3):286-& VICKERS TH ALIMENTARY TRACT MALFORMATIONS IN RABBIT THALIDOMIDE EMBRYOPATHY | 0 | 2 |
| 2435 | 0 | 0 | 841 1984 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 111(3):289-290 VIGNOLLY B; GENIAUX M; ROMMEL A; TEXIER L BEHCET DISEASE, NODOUS ERYTHEMA AND THALIDOMIDE | 0 | 0 |
| 2436 | 11 | 26 | 1163 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):543-548 VILANOVA M; RIBEIRO A; CARNEIRO J; ARALACHAVES M THE EFFECTS OF THALIDOMIDE TREATMENT ON AUTOIMMUNE-PRONE NZB AND MRL MICE ARE CONSISTENT WITH STIMULATION OF THE CENTRAL IMMUNE-SYSTEM .2. | 4 | 5 |
| 2437 | 0 | 5 | 234 1963 LANCET 1(728):725-& VILLA L; ERIDANI S CYTOLOGICAL EFFECTS OF THALIDOMIDE | 4 | 7 |
| 2438 | 0 | 0 | 2177 2002 EUROPEAN JOURNAL OF CANCER 38:S53-S53 Villalona-Calero M; Duan W; Otterson G; Kleiber B; Hindman K; Shah M; Young D; Wu W; Kuhn J Thalidomide modulation of Irinotecan; an NF-kB dependent effect? | 0 | 0 |
| 2439 | 4 | 5 | 967 1988 DERMATOLOGICA 176(2):107-107 VIRABEN R; DUPRE A ERYTHEMA-NODOSUM FOLLOWING THALIDOMIDE THERAPY FOR BEHCET DISEASE | 1 | 5 |
| 2440 | 5 | 8 | 2518 2003 LEUKEMIA 17(8):1669-1670 Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2441 | 2 | 14 | 394 1966 LANCET 1(7444):981-& VLADUTIU A ANOTHER CHANCE FOR THALIDOMIDE | 2 | 2 |
| 2442 | 0 | 0 | 885 1985 FEDERATION PROCEEDINGS 44(6):1881-1881 VOGELSANG G; GORDON G; HORWITZ L; SANTOS G; HESS A IMMUNOSUPPRESSIVE ACTIVITY OF THALIDOMIDE | 0 | 2 |
| 2443 | 2 | 2 | 1072 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(10):735-735 VOGELSANG GB THALIDOMIDE NEUROPATHY - REPLY | 2 | 2 |
| 2444 | 0 | 0 | 1043 1991 EXPERIMENTAL HEMATOLOGY 19(6):553-553 VOGELSANG GB; BUJNOVSZKY C; BOUCHER C; LEONG K; JALALIAN M; HESS A; SANTOS GW INVITRO IMMUNOLOGICAL EFFECTS OF THALIDOMIDE | 0 | 0 |
| 2445 | 0 | 0 | 1088 1993 BLOOD 82(10):A421-A421 VOGELSANG GB; COLVIN OM; ALTOMONTE V; PIANTADOSI S; HESS AD; SANTOS GW EFFECT OF THALIDOMIDE DOSE AND PLASMA-LEVEL ON PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 2446 | 9 | 21 | 1070 1992 NEW ENGLAND JOURNAL OF MEDICINE 326(16):1055-1058 VOGELSANG GB; FARMER ER; HESS AD; ALTAMONTE V; BESCHORNER WE; JABS DA; CORIO RL; LEVIN LS; COLVIN OM; WINGARD JR; SANTOS GW THALIDOMIDE FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE | 166 | 253 |
| 2447 | 2 | 6 | 953 1987 TRANSPLANTATION PROCEEDINGS 19(1):2658-2661 VOGELSANG GB; HESS AD; GORDON G; BRUNDRETTE R; SANTOS GW THALIDOMIDE INDUCTION OF BONE-MARROW TRANSPLANTATION TOLERANCE | 24 | 32 |
| 2448 | 8 | 20 | 935 1986 TRANSPLANTATION 41(5):644-647 VOGELSANG GB; HESS AD; GORDON G; SANTOS GW TREATMENT AND PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH THALIDOMIDE IN A RAT MODEL | 47 | 71 |
| 2449 | 11 | 19 | 963 1988 BONE MARROW TRANSPLANTATION 3(5):393-398 VOGELSANG GB; HESS AD; SANTOS GW THALIDOMIDE FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 31 | 38 |
| 2450 | 3 | 6 | 972 1988 LANCET 1(8589):827-827 VOGELSANG GB; SANTOS GW; COLVIN OM; CHEN TL THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 12 | 25 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2451 | 1 | 7 | 936 1986 TRANSPLANTATION PROCEEDINGS 18(4):904-906 VOGELSANG GB; TAYLOR S; GORDON G; HESS AD THALIDOMIDE, A POTENT AGENT FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 19 | 27 |
| 2452 | 4 | 8 | 985 1988 TRANSPLANTATION PROCEEDINGS 20(2):226-228 VOGELSANG GB; WELLS MC; SANTOS GW; CHEN TL; HESS AD COMBINATION LOW-DOSE THALIDOMIDE AND CYCLOSPORINE PROPHYLAXIS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN A RAT MISMATCHED MODEL | 14 | 16 |
| 2453 | 17 | 24 | 2018 2002 AKTUELLE NEUROLOGIE 29(3):149-152 Vogt T; Nill M; Hundsberger T Thalidomide neuropathy | 0 | 0 |
| 2454 | 7 | 12 | 823 1983 HAUTARZT 34(4):175-178 VOLCPLATZER B; WOLFF K TREATMENT OF SUBACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 3 | 6 |
| 2455 | 77 | 104 | 2562 2003 SWISS MEDICAL WEEKLY 133(5-6):77-87 von Moos R; Stolz R; Cerny T; Gillessen S Thalidomide: from tragedy to promise | 1 | 1 |
| 2456 | 1 | 26 | 1984 2001 NEUROTOXICOLOGY AND TERATOLOGY 23(3):255-264 Vorhees CV; Weisenburger WP; Minck DR Neurobehavioral teratogenic effects of thalidomide in rats | 1 | 3 |
| 2457 | 0 | 0 | 1156 1994 PANMINERVA MEDICA 36(1):1-4 VOSGERAU JCB AUTOIMMUNITY IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND THE USE OF THALIDOMIDE | 3 | 3 |
| 2458 | 0 | 0 | 1157 1994 PANMINERVA MEDICA 36(1):44-47 VOSGERAU JCB ATYPICAL HERPES SIMPLE - A SIGN OF TOXOPLASMOSIS ACTIVITY IN AIDS PATIENTS AND THE USE OF THALIDOMIDE | 0 | 1 |
| 2459 | 0 | 10 | 1361 1997 JOURNAL OF PARENTERAL AND ENTERAL NUTRITION 21(4):233-234 Vromen A; Spira RM; Bercovier H; Berry E; Freund HR Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat | 0 | 2 |
| 2460 | 11 | 15 | 2601 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(2):149-155 Waage A; Gimsing P; Juliusson G; Turesson I; Gulbrandsen N; Eriksson T; Hjorth M; Nielsen JL; Lenhoff S; Westin J; Wisloff F; Nordic Myeloma Study Grp Early response predicts thalidomide efficiency in patients with advanced multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2461 | 0 | 0 | 2087 2002 BLOOD 100(11):380B-380B Waage A; Romstad L; Brenne AT; Gimsing P; Juliusson G; Turesson I; Borset M; Sundan A Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 0 | 1 |
| 2462 | 18 | 27 | 1728 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(5):383-388 Walchner M; Meurer M; Plewig G; Messer G Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus | 16 | 27 |
| 2463 | 2 | 3 | 383 1966 JOURNAL OF ECONOMIC ENTOMOLOGY 59(4):1006-& WALDRON WG; SMITH RE; NOWLIN LA; RICE EH THALIDOMIDE AS A GROWTH MODIFIER IN GERMAN COCKROACH | 0 | 0 |
| 2464 | 1 | 2 | 809 1983 BRITISH MEDICAL JOURNAL 287(6400):1225-1225 WALKER W; LEWIS HBM; ALBERTRECHT F EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 0 | 0 |
| 2465 | 3 | 6 | 69 1962 BRITISH MEDICAL JOURNAL (5305):646-& WARD SP THALIDOMIDE AND CONGENITAL ABNORMALITIES | 3 | 3 |
| 2466 | 3 | 17 | 981 1988 TERATOLOGY 38(3):217-219 WARKANY J WHY I DOUBTED THAT THALIDOMIDE WAS THE CAUSE OF THE EPIDEMIC OF LIMB DEFECTS OF 1959 TO 1961 | 2 | 3 |
| 2467 | 7 | 10 | 1454 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(2):293-295 Warren KJ; Nopper AJ; Crosby DL Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus | 7 | 9 |
| 2468 | 4 | 10 | 1039 1991 BRITISH MEDICAL JOURNAL 303(6800):470-470 WATERS MFR USE OF THALIDOMIDE IN LEPROSY | 5 | 5 |
| 2469 | 0 | 0 | 1079 1992 TROPICAL DOCTOR 22(3):139-140 WATERS MFR THALIDOMIDE PERIPHERAL NEUROPATHY - REPLY | 2 | 4 |
| 2470 | 1 | 4 | 692 1979 BRITISH MEDICAL JOURNAL 1(6166):792-792 WATERS MFR; LAING ABG; AMBIKAPATHY A; LENNARDJONES JE TREATMENT OF ULCERATIVE-COLITIS WITH THALIDOMIDE | 27 | 36 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2471 | 0 | 0 | 510 1970 NEW SOCIETY 16(417):543-543 WATSON P THWARTING THALIDOMIDE THREAT | 0 | 0 |
| 2472 | 10 | 16 | 210 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 89(19):987-& WEBB JF CANADIAN THALIDOMIDE EXPERIENCE | 0 | 5 |
| 2473 | 0 | 0 | 325 1965 CANADIAN MEDICAL ASSOCIATION JOURNAL 92(11):585-& WEBB JF THALIDOMIDE PROBLEM IN CANADA | 0 | 0 |
| 2474 | 0 | 0 | 2120 2002 BLOOD 100(11):808A-809A Weber D; Albitar M; Delasalle K; Dey A; Rankin K; Gavino M; Walker P; Alexanian R Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM). | 0 | 1 |
| 2475 | 0 | 0 | 2072 2002 BLOOD 100(11):209A-209A Weber D; Ginsberg C; Walker P; Obolendt M; Rankin K; Gavino M; Delasalle K; Alexanian R Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD). | 0 | 2 |
| 2476 | 7 | 22 | 2476 2003 JOURNAL OF CLINICAL ONCOLOGY 21(1):16-19 Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | 29 | 55 |
| 2477 | 0 | 0 | 1518 1999 BLOOD 94(10):604A-604A Weber DM; Gavino M; Delasalle K; Rankin K; Giralt S; Alexanian R Thalidomide alone or with dexamethasone for multiple myeloma. | 0 | 27 |
| 2478 | 0 | 0 | 1640 2000 BLOOD 96(11):168A-168A Weber DM; Rankin K; Gavino M; Delasalle K; Aguayo A; Albitar M; Alexanian R Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). | 0 | 10 |
| 2479 | 0 | 0 | 1637 2000 BLOOD 96(11):167A-167A Weber DM; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide with dexamethasone for resistant multiple myeloma. | 0 | 26 |
| 2480 | 12 | 17 | 2527 2003 LEUKEMIA & LYMPHOMA 44(7):1147-1149 Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2481 | 0 | 0 | 1837 2001 BLOOD 98(11):162A-162A Wechalekar AD; Sutton D; Voralia M; Stewart AK; Chen CI Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. | 0 | 5 |
| 2482 | 0 | 0 | 1542 1999 GASTROENTEROLOGY 116(4):A843-A843 Wedel S; Bauditz J; Suk A; Lochs H Efficacy of thalidomide in Crohn's disease. | 2 | 3 |
| 2483 | 11 | 52 | 2501 2003 JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
| 2484 | 11 | 35 | 1106 1993 MOLECULAR AND CELLULAR BIOCHEMISTRY 129(2):195-200 WEGLICKI WB; STAFFORD RE; DICKENS BF; MAK IT; CASSIDY MM; PHILLIPS TM INHIBITION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE IN MAGNESIUM-DEFICIENCY | 4 | 9 |
| 2485 | 19 | 32 | 2498 2003 JOURNAL OF RHEUMATOLOGY 30(12):2627-2631 Wei JCC; Chan TW; Lin HS; Huang F; Chou CT Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial | 0 | 1 |
| 2486 | 0 | 0 | 698 1979 HNO 27(9):302-307 WEIDENBECHER M; MAAK G BEHAVIOR OF THE FACIAL-NERVE IN VITAMIN-A AND THALIDOMIDE INDUCED ATRESIA AURIS CONGENITA - MICROSURGICAL AND HISTOLOGICAL ANIMAL STUDY | 1 | 1 |
| 2487 | 9 | 12 | 1230 1996 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 53(4):368-& Weidle PJ Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus | 5 | 5 |
| 2488 | 2 | 4 | 245 1963 MAYO CLINIC PROCEEDINGS 38(23):518-& WEIDMAN WH; YOUNG HH; ZOLLMAN PE EFFECT OF THALIDOMIDE ON UNBORN PUPPY | 5 | 3 |
| 2489 | 13 | 23 | 1569 1999 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
| 2490 | 0 | 0 | 756 1981 JOURNAL OF POST KEYNESIAN ECONOMICS 3(3):459-462 WEINTRAUB S THE CARTER ECONOMIC COUNCILS THALIDOMIDE TIP | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2491 | 0 | 32 | 763 1981 REHABILITATION 20(3):128-132 WEINWURMKRAUSE EM PARTNERSHIP AND SEXUALITY OF THALIDOMIDE-AFFECTED YOUNG-PEOPLE | 0 | 0 |
| 2492 | 0 | 18 | 764 1981 REHABILITATION 20(4):159-164 WEINWURMKRAUSE EM THE SITUATION OF THALIDOMIDE-AFFECTED YOUNG-PEOPLE IN CHOOSING AN OCCUPATION | 0 | 2 |
| 2493 | 5 | 19 | 1201 1995 JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 674(2):287-292 Weinz C; Blaschke G Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis | 11 | 24 |
| 2494 | 0 | 0 | 1352 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):20-20 Welles L; Little R; Wyvill K; Pluda J; Figg W; Lietzau J; Merced T; Humphrey R; Yarchoan R Preliminary results of a phase II study of oral thalidomide in patients with HIV infection and Kaposi's sarcoma (KS) | 2 | 3 |
| 2495 | 17 | 19 | 1734 2000 JOINT BONE SPINE 67(4):259-261 Wendling D; Toussirot E; Michel F Thalidomide: a comeback? | 1 | 4 |
| 2496 | 0 | 0 | 1221 1995 SEARCH 26(10):290-290 WESTMORE A HEREDITY OF THALIDOMIDE DEFORMITY DISPUTED | 0 | 0 |
| 2497 | 2 | 5 | 1367 1997 LANCET 350(9089):1445-1446 Wettstein AR; Meagher AP Thalidomide in Crohn's disease | 34 | 52 |
| 2498 | 0 | 0 | 130 1962 LANCET 2(7245):46-& WHATLEY E THALIDOMIDE-DAMAGED BABIES | 1 | 2 |
| 2499 | 0 | 1 | 487 1969 LANCET 2(7615):331-& WHICHER H DAMAGES AWARDED FOR THALIDOMIDE CHILDREN | 0 | 0 |
| 2500 | 0 | 0 | 1364 1997 JOURNAL OF WOMENS HEALTH 6(6):614-615 White K Thalidomide may be approved after decades-long US ban | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2501 | 0 | 0 | 67 1962 BRITISH MEDICAL JOURNAL (5303):522-& WHITEFRA.A THALIDOMIDE BABIES MEMORANDUM FROM BRITISH PAEDIATRIC ASSOCIATION | 0 | 0 |
| 2502 | 0 | 0 | 65 1962 BRITISH MEDICAL JOURNAL (5299):261-& WHITEFRA.A; RATTENBURY G HELP FOR THALIDOMIDE BABIES | 0 | 0 |
| 2503 | 0 | 0 | 170 1962 NEW ENGLAND JOURNAL OF MEDICINE 267(25):1320-& WHITEHILL LA THALIDOMIDE AND PHOCOMELIA | 0 | 0 |
| 2504 | 0 | 1 | 297 1964 NEW ENGLAND JOURNAL OF MEDICINE 271(18):963-& WHITEHILL LA; INGALLS TH THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 2505 | 0 | 9 | 49 1961 Med Welt 37:1863-1866 WIEDEMANN HR Indications of a current increase of hypoplastic and aplastic deformities of the extremities | 37 | 86 |
| 2506 | 0 | 0 | 140 1962 LANCET 2(7251):349-& WIGGLESWORTH R THALIDOMIDE-DAMAGED INFANTS | 2 | 2 |
| 2507 | 1 | 2 | 62 1962 BRITISH MEDICAL JOURNAL (5294):1758-& WIGGLESWORTH R; WRIGHT GB THALIDOMIDE (DISTAVAL) AND FOETAL ABNORMALITIES | 0 | 0 |
| 2508 | 1 | 4 | 1047 1991 LANCET 337(8738):436-437 WILLIAMS I; WELLER IVD; MALIN A; ANDERSON J; WATERS MFR THALIDOMIDE HYPERSENSITIVITY IN AIDS | 26 | 34 |
| 2509 | 0 | 0 | 483 1969 FEDERATION PROCEEDINGS 28(2):743-& WILLIAMS JP THALIDOMIDE AND DNA SYNTHESIS | 0 | 1 |
| 2510 | 0 | 0 | 217 1963 FEDERATION PROCEEDINGS 22(2):368-& WILLIAMS M; SPARLING F; WEST FR INTRAVENOUS ADMINISTRATION OF ALPHA-PHTHALIMIDOGLUTARIMIDE (THALIDOMIDE) | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2511 | 0 | 1 | 232 1963 LANCET 1(728):723-& WILLIAMS RT TERATOGENIC EFFECTS OF THALIDOMIDE AND RELATED SUBSTANCES | 18 | 39 |
| 2512 | 15 | 31 | 449 1968 ARCHIVES OF ENVIRONMENTAL HEALTH 16(4):493-& WILLIAMS RT THALIDOMIDE - A STUDY OF BIOCHEMICAL TERATOLOGY | 9 | 20 |
| 2513 | 4 | 6 | 56 1962 BRITISH MEDICAL JOURNAL (5276):477-& WILLMAN A; DUMOULIN JG THALIDOMIDE (DISTAVAL) AND FOETAL ABNORMALITIES | 0 | 0 |
| 2514 | 8 | 12 | 2139 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(1):128-130 Wilson EA; Jobanputra S; Jackson R; Parker AN; McQuaker IG Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report | 1 | 3 |
| 2515 | 0 | 0 | 417 1967 ANATOMICAL RECORD 157(2):342-& WILSON JG; GAVAN JA THALIDOMIDE SYNDROME OF MALFORMATIONS PRODUCED IN RHESUS MONKEYS | 0 | 7 |
| 2516 | 0 | 0 | 1466 1998 MOLECULAR BIOLOGY OF THE CELL 9:200A-200A Wilson K; Lancaster T; Boyd M; Taylor LD Inhibition of cell-cell contacts in T lymphoblastic cells during exposure to thalidomide. | 0 | 0 |
| 2517 | 10 | 15 | 996 1989 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 488(2):417-425 WINCKLER K; KLINKMULLER KD; SCHMAHL HJ DETERMINATION OF THE THALIDOMIDE ANALOGS 2-(2,6-DIOXOPIPERIDINE-3-YL)PHTHALIMIDINE (EM 12), 2-(2,6-DIOXOPIPERIDINE-4-YL)PHTHALIMIDINE (EM 16) AND THEIR METABOLITES IN BIOLOGICAL SAMPLES | 7 | 7 |
| 2518 | 8 | 13 | 839 1984 ACTA DERMATO-VENEREOLOGICA 64(5):412-417 WINKELMANN RK; CONNOLLY SM; DOYLE JA; PADILHAGONCALVES A THALIDOMIDE TREATMENT OF PRURIGO NODULARIS | 17 | 27 |
| 2519 | 3 | 5 | 1064 1992 LANCET 339(8789):365-365 WINTER W; FRANKUS E THALIDOMIDE ENANTIOMERS | 12 | 18 |
| 2520 | 18 | 31 | 2574 2004 ANNALS OF HEMATOLOGY 83(7):467-470 Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2521 | 15 | 22 | 1253 1996 CHIRALITY 8(5):390-396 Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues | 27 | 33 |
| 2522 | 5 | 9 | 1372 1997 NATURE 385(6614):303-304 Wnendt S; Zwingenberger K Thalidomide's chirality | 9 | 16 |
| 2523 | 13 | 15 | 2232 2002 JOURNAL OF INFECTIOUS DISEASES 185(9):1359-1363 Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H; Natl Inst Allergy Infect Dis AIDS Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267 | 5 | 5 |
| 2524 | 0 | 0 | 178 1962 SCIENCE 137(3529):497-& WOLFLE D THALIDOMIDE LESSON | 0 | 0 |
| 2525 | 0 | 0 | 1447 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):516-516 Wolkenstein P; Latarget J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Milpied B; Bocquet H; Revuz J Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: Overmortality in treated group. | 0 | 0 |
| 2526 | 8 | 28 | 1462 1998 LANCET 352(9140):1586-1589 Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis | 39 | 78 |
| 2527 | 0 | 0 | 1863 2001 BLOOD 98(11):313B-313B Womeldorph JL; Myhand RC; Monahan BP Reversible acute renal failure following initiation of thalidomide therapy in a patient with relapsed multiple myeloma. | 0 | 0 |
| 2528 | 0 | 0 | 1360 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):797-797 Wong J; Brocato D; Kumar R The effect of thalidomide on murine hemangioendothelioma | 0 | 0 |
| 2529 | 20 | 38 | 1023 1990 LEUKEMIA RESEARCH 14(5):395-399 WOOD PMD; PROCTOR SJ THE POTENTIAL USE OF THALIDOMIDE IN THE THERAPY OF GRAFT-VERSUS-HOST DISEASE - A REVIEW OF CLINICAL AND LABORATORY INFORMATION | 17 | 26 |
| 2530 | 0 | 0 | 263 1963 SOCIAL EDUCATION 27(3):131-133 WOODWORTH JR THALIDOMIDE IN RETROSPECT | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2531 | 0 | 0 | 125 1962 LANCET 1(7232):750-& WOODYATT PB THALIDOMIDE | 6 | 8 |
| 2532 | 0 | 0 | 64 1962 BRITISH MEDICAL JOURNAL (5299):236-& WOOLLAM DHM THALIDOMIDE DISASTER CONSIDERED AS AN EXPERIMENT IN MAMMALIAN TERATOLOGY | 0 | 0 |
| 2533 | 0 | 0 | 76 1962 BRITISH MEDICAL JOURNAL (5309):920-& WOOLLAM DHM THALIDOMIDE AND MOUSE | 2 | 2 |
| 2534 | 0 | 0 | 80 1962 BRITISH MEDICAL JOURNAL (5315):1321-& WOOLLAM DHM CENSUS OF THALIDOMIDE MOTHERS | 0 | 1 |
| 2535 | 1 | 7 | 354 1965 PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON 58(7):497-& WOOLLAM DHM PRINCIPLES OF TERATOGENESIS - MODE OF ACTION OF THALIDOMIDE | 6 | 12 |
| 2536 | 4 | 9 | 2408 2003 BRITISH JOURNAL OF DERMATOLOGY 148(3):601-602 Worm M; Kolde G Schnitzler's syndrome: successful treatment of two patients using thalidomide | 0 | 0 |
| 2537 | 0 | 0 | 2649 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(3):P78-P78 Wu JJ; Pang KR; Hsu S; Tyring SK Thalidomide: A review of new indications | 0 | 0 |
| 2538 | 0 | 0 | 1511 1999 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
| 2539 | 3 | 10 | 459 1968 EXPERIENTIA 24(10):993-& WUEST HM; FOX RR; CRARY DD RELATIONSHIP BETWEEN TERATOGENY AND STRUCTURE IN THALIDOMIDE FIELD | 7 | 14 |
| 2540 | 0 | 3 | 491 1969 TERATOLOGY 2(3):273-& WUEST HM; FOX RR; CRARY DD THALIDOMIDE - LACK OF TERATOGENIC ACTION OF N-CARBETHOXYPHTHALIMIDE (WU374) IN NEW ZEALAND RABBIT | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2541 | 0 | 0 | 587 1973 TERATOLOGY 8(2):242-242 WUEST HM; MCNULTY WP EXPERIMENTAL TERATOLOGY AND THALIDOMIDE PROBLEM | 0 | 0 |
| 2542 | 0 | 2 | 471 1968 TERATOLOGY 1(2):223-& WUEST HM; TARNOWSK.S TOXICITY OF OPTICAL ACTIVE FORMS OF THALIDOMIDE | 0 | 0 |
| 2543 | 17 | 30 | 878 1985 BRITISH JOURNAL OF DERMATOLOGY 112(4):475-480 WULFF CH; HOYER H; ASBOEHANSEN G; BRODTHAGEN H DEVELOPMENT OF POLYNEUROPATHY DURING THALIDOMIDE THERAPY | 66 | 85 |
| 2544 | 2 | 37 | 829 1983 PERSPECTIVES IN BIOLOGY AND MEDICINE 27(1):93-106 WYATT HV DID THALIDOMIDE PROMOTE POLIOMYELITIS FOLLOWING ORAL POLIOVIRUS VACCINATION IN WEST-BERLIN IN 1960 | 0 | 4 |
| 2545 | 0 | 0 | 512 1970 TERATOLOGY 3(2):211-& WYNN RL; BLAKE DA A METABOLITE OF THALIDOMIDE HAVING POSSIBLE TERATOLOGICAL SIGNIFICANCE | 0 | 0 |
| 2546 | 13 | 21 | 2227 2002 JOURNAL OF COMBINATORIAL CHEMISTRY 4(2):149-153 Xiao ZL; Schaefer K; Firestine S; Li PK Solid-phase synthesis of thalidomide and its analogues | 0 | 4 |
| 2547 | 0 | 0 | 1799 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U659-U659 Xiao ZL; Schaefer K; Li PK Solid phase synthesis of thalidomide and its analogs. | 0 | 0 |
| 2548 | 0 | 0 | 1514 1999 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
| 2549 | 26 | 39 | 2125 2002 BLOOD 100(12):4162-4168 Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J Antimyeloma efficacy of thalidomide in the SCID-hu model | 1 | 6 |
| 2550 | 0 | 0 | 1638 2000 BLOOD 96(11):167A-167A Yakoub-Agha I; Attal M; Dumontet C; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux I; Bay JO; Monconduit M; Harousseau JL; Duguet C; Facon T Thalidomide in patients with advanced myeloma: Survival prognostic factors. | 0 | 11 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2551 | 0 | 0 | 2590 2004 BONE MARROW TRANSPLANTATION 33:S156-S156 Yakoub-Agha I; Mohty M; Attal M; Marit G; Bulabois C; Sotto JJ; Gratecos N; Rio B; Vernant JP; Facon T; Jouet JP; Intergrp Francophne Myelome & SGFM Thalidomide as salvage therapy for relapsed multiple myeloma after allogeneic stem cell transplantation | 0 | 0 |
| 2552 | 0 | 0 | 2379 2003 BLOOD 102(11):456B-456B Yakoub-agha I; Mohty M; Attal M; Marit G; Bulabois CE; Sotto JJ; Gratecos N; Rio B; Vernant JP; Dib M; Garban F; Cahn JY; Jouet JP; Facon T Thalidomide (THAL) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT). | 0 | 0 |
| 2553 | 12 | 23 | 2565 2003 XENOTRANSPLANTATION 10(5):470-474 Yamamoto S; Cooper DKC An investigation of the effect of thalidomide on anti-gal antibody production in baboons | 0 | 0 |
| 2554 | 0 | 0 | 1099 1993 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 34(4):1479-1479 YAN GC; PITTET N; HERBORT CP THE EFFECT OF THALIDOMIDE ON ENDOTOXIN-INDUCED UVEITIS IN RATS | 0 | 0 |
| 2555 | 0 | 0 | 1903 2001 CIRCULATION 104(17):123-123 Yang E; Matcuk G; Zhang Y; Talbi S; Chen M; Ho M; Liao C; Tsao PS; Quertermous T; Deng D; Sampas N; Ach R; Love W Anti-angiogenic effects of thalidomide characterized by transciptional profiling of endothelial cell-specific gene expression | 0 | 0 |
| 2556 | 0 | 0 | 1229 1996 AMERICAN JOURNAL OF EPIDEMIOLOGY 143(11):6-6 Yang Q; Khoury MJ; James LM; Olney RS; Paulozzi LJ The return of thalidomide? Are birth defects surveillance systems ready? | 0 | 1 |
| 2557 | 3 | 44 | 1309 1997 AMERICAN JOURNAL OF MEDICAL GENETICS 73(3):251-258 Yang QH; Khoury MJ; James LM; Olney RS; Paulozzi LJ; Erickson JD The return of thalidomide: Are birth defects surveillance systems ready? | 1 | 6 |
| 2558 | 2 | 3 | 229 1963 LANCET 1(728):552-& YANG T; LIANG H THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 8 |
| 2559 | 0 | 0 | 2502 2003 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14:807A-807A Yaqub MS Acute renal failure in multiple myeloma patient receiving thalidomide and zoledronic acid infusion. | 0 | 0 |
| 2560 | 0 | 0 | 682 1978 TERATOLOGY 18(1):136-136 YASUDA M EMBRYOLOGY OF THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2561 | 2 | 5 | 2494 2003 JOURNAL OF PEDIATRICS 143(5):692-694 Yasui K; Misawa Y; Shimizu T; Komiyama A; Kawakami T; Mizoguchi M Thalidomide therapy for juvenile-onset entero-Behcet disease | 0 | 0 |
| 2562 | 5 | 41 | 2470 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 22(1):165-173 Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells | 2 | 3 |
| 2563 | 0 | 0 | 1666 2000 BLOOD 96(11):364A-364A Yata K; Otsuki T; Yamada O; Yawata Y Expression of angiogenic factors including VEGFs, effects of anti-VEGF-A MoAb, hypoxia, and thalidomide on myeloma cells. | 0 | 0 |
| 2564 | 1 | 1 | 103 1962 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 181(7):654-& YONKMAN FF THALIDOMIDE AND RELATED COMPOUNDS | 0 | 0 |
| 2565 | 6 | 8 | 66 1962 BRITISH MEDICAL JOURNAL (5300):306-& YORKE RA; KILSHAW D; TAYLOR WH; SUTTON WS NEUROPATHY, HYPOGLYCAEMIA, AND ADRENAL DYSFUNCTION DURING TREATMENT WITH THALIDOMIDE | 0 | 0 |
| 2566 | 3 | 42 | 883 1985 EUROPEAN JOURNAL OF PHARMACOLOGY 119(1-2):39-46 YOUDIM MBH; ASHKENAZI R SEROTONERGIC INVOLVEMENT IN PHARMACOLOGICAL ACTION OF THE ANXIOLYTIC-SEDATIVES THALIDOMIDE AND SUPIDIMIDE | 0 | 1 |
| 2567 | 4 | 5 | 992 1989 BRITISH MEDICAL JOURNAL 298(6671):432-432 YOULE M; CLARBOUR J; FARTHING C; CONNOLLY M; HAWKINS D; STAUGHTON R; GAZZARD B TREATMENT OF RESISTANT APHTHOUS ULCERATION WITH THALIDOMIDE IN PATIENTS POSITIVE FOR HIV ANTIBODY | 56 | 103 |
| 2568 | 1 | 4 | 1022 1990 LANCET 335(8705):1591-1591 YOULE M; HAWKINS D; GAZZARD B THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 9 | 11 |
| 2569 | 0 | 0 | 2023 2002 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 59(18):1700-+ Young D Thalidomide prescribers cannot assign survey responsibility to pharmacists | 0 | 0 |
| 2570 | 1 | 1 | 2421 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):563-563 Younis T; Alam A; Paplham P; Spangenthal E; McCarthy P Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma (vol 121, pg 191, 2003) | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2571 | 3 | 5 | 2414 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):191-192 Younis TH Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma | 1 | 2 |
| 2572 | 0 | 0 | 2248 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:733A-734A Yudis M; Sirota RA; Stein HD; Snipes ER; Gronich JH; Ghantous VE; Collins DM Renal failure (RF) in multiple myeloma (MM) - Possible association with pamidronate and thalidomide. | 0 | 0 |
| 2573 | 3 | 6 | 2056 2002 BLOOD 99(11):4249-4249 Zangari M Thalidomide and thromboembolism - Response | 0 | 0 |
| 2574 | 3 | 5 | 1832 2001 BLOOD 98(5):1614-1615 Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy | 59 | 90 |
| 2575 | 0 | 0 | 1659 2000 BLOOD 96(11):296B-296B Zangari M; Anaissie E; Desikan R; Badros A; Morris C; Munshi N; Gopal AV; Fink L; Spoon D; Tricot G; Barlogie B Thalidomide-induced hypercoagulability in multiple myeloma (MM). | 0 | 3 |
| 2576 | 0 | 0 | 2107 2002 BLOOD 100(11):398A-398A Zangari M; Barlogie B; Anaissie FJ; Saghafifar F; Fassas A; Lee CK; Thertulien R; van Rhee F; Zeldis J; Fink L; Tricot G Abrogation of thrombogenic effect of the doxorubicin (DOX)- thalidomide (THAL) combination as part of total therapy II (TTII) for newley diagnosed multiple myeloma (MM) by effective anti-coagulation with low molecular weight heparin (LMWH). | 0 | 2 |
| 2577 | 0 | 0 | 2346 2003 BLOOD 102(11):236A-236A Zangari M; Barlogie B; Jacobson J; Rasmussen E; Burns M; Kordsmeier B; Shaughnessy JD; Anaissie EJ; Thertulien R; Fassas A; Lee CK; Schenkein D; Zeldis JB; Tricot G VTD regimen comprising velcade (V) plus thalidomide (T) and added DEX (D) for non-responders to V+T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. | 0 | 3 |
| 2578 | 0 | 0 | 2386 2003 BLOOD 102(11):687A-687A Zangari M; Barlogie B; Lee CK; Kang SH; Fassas A; Thertulien R; Van Rhee F; Talamo G; Burns M; Anaissie EJ; Tricot G; Jacobson J Increment in bone phophatase (ALP) in myeloma patients during treatment with velcade, thalidomide and dexamethasome (VTD) is a strong predictor for response. | 0 | 0 |
| 2579 | 0 | 0 | 2067 2002 BLOOD 100(11):105A-105A Zangari M; Barlogie B; Prather J; Eddlemon P; Anaissie E; Lee CK; Tricot G; Thertulien R; van Rhee F Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. | 0 | 5 |
| 2580 | 5 | 20 | 2440 2003 CLINICAL LYMPHOMA 4(1):32-35 Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival | 1 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2581 | 0 | 0 | 1835 2001 BLOOD 98(11):161A-162A Zangari M; Siegel E; Anaissie E; Saghafifar F; Morris C; Fink L; Barlogie B; Tricot G Risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (pts) treated with thalidomide (Thal): The Arkansas experience. | 0 | 4 |
| 2582 | 4 | 23 | 2058 2002 BLOOD 100(4):1168-1171 Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy | 17 | 31 |
| 2583 | 0 | 0 | 1939 2001 HAEMATOLOGICA 86(4):448-448 Zappasodi P; Lorenzi A; Corso A Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity | 1 | 1 |
| 2584 | 6 | 17 | 1532 1999 CLINICAL THERAPEUTICS 21(2):319-330 Zeldis JB; Williams BA; Thomas SD; Elsayed ME STEPS (TM): A comprehensive program for controlling and monitoring access to thalidomide | 37 | 45 |
| 2585 | 11 | 28 | 2575 2004 ANNALS OF ONCOLOGY 15(1):134-138 Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou A; Mitsouli C; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A; Greek Myeloma Study Grp Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study | 0 | 0 |
| 2586 | 0 | 0 | 2373 2003 BLOOD 102(11):450A-450A Zervas K; Dimopoulos MA; Hatziharisi E; Anagnostopoulos A; Papaioannou M; Mitsouli C; Panagiotidis P; Korantzis L; Tzilianos M; Maniatis A Primary treatment of mutiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. | 0 | 0 |
| 2587 | 1 | 6 | 359 1966 ACTA OPHTHALMOLOGICA 44(3):391-& ZETTERST.B OCULAR MALFORMATIONS CAUSED BY THALIDOMIDE | 0 | 18 |
| 2588 | 0 | 0 | 1275 1996 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 37(3):4015-4015 Zhang EP; Pleyer U; Hoffmann F; Hartmann C Effect of thalidomide on experimental keratoplasty | 0 | 0 |
| 2589 | 0 | 0 | 2187 2002 FERTILITY AND STERILITY 77(2):S28-S28 Zhong S; Shen K; Lang J The effects of thalidomide on interleukin-6 and vascular endothelial growth factor expression of endometrial stromal cell in vitro. | 0 | 0 |
| 2590 | 8 | 37 | 1897 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(4):319-326 Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac | 2 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2591 | 8 | 8 | 2436 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Zhou SF Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. | 0 | 0 |
| 2592 | 5 | 10 | 2451 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Zhou SF CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation | 0 | 0 |
| 2593 | 11 | 31 | 1898 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(6):541-544 Zhou SF; Kestell P; Tingle MD; Ching LM; Paxton JW A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide | 2 | 5 |
| 2594 | 110 | 164 | 2176 2002 DRUGS & AGING 19(2):85-100 Zhou SF; Kestell P; Tingle MD; Paxton JW Thalidomide in cancer treatment - A potential role in the elderly? | 4 | 5 |
| 2595 | 0 | 0 | 2174 2002 DRUG METABOLISM REVIEWS 34:148-148 Zhou SF; Li Y; Kestell P; Paxton JW Preliminary study of thalidomide transport by the human intestinal cell line Caco-2 | 0 | 0 |
| 2596 | 59 | 70 | 2475 2003 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
| 2597 | 19 | 42 | 1329 1997 CLINICAL NEUROPHARMACOLOGY 20(2):152-164 Zhu J; Bai XF; Mix E; vanderMeide PH; Zwingenberger K; Link H Thalidomide suppresses T-and B-cell responses to myelin antigen in experimental allergic neuritis | 3 | 4 |
| 2598 | 18 | 33 | 1477 1998 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 48(4):397-402 Zhu J; Deng GM; Diab A; Zwingenberger K; Bakhiet M; Link H Thalidomide prolongs experimental autoimmune neuritis in Lewis rats | 4 | 10 |
| 2599 | 16 | 45 | 2491 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(24):5222-5229 Zhu XX; Giordano T; Yu QS; Holloway HW; Perry TA; Lahiri DK; Brossi A; Greig NH Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity | 2 | 2 |
| 2600 | 30 | 79 | 1581 1999 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 425(1):153-167 Zhu XY; Zhang YP; Klopman G; Rosenkranz HS Thalidomide and metabolites: indications of the absence of 'genotoxic' carcinogenic potentials | 3 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2601 | 2 | 6 | 1679 2000 BONE MARROW TRANSPLANTATION 25(12):1319-1320 Zomas A; Anagnostopoulos N; Dimopoulos MA Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent | 18 | 32 |
| 2602 | 15 | 82 | 2045 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):20-30 Zorat F; Pozzato G Thalidomide in myelodysplastic syndromes | 3 | 3 |
| 2603 | 8 | 53 | 1894 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(4):881-894 Zorat F; Shetty V; Dutt D; Lisak L; Nascimben F; Allampallam K; Dar S; York A; Gezer S; Venugopal P; Raza A The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes | 13 | 22 |
| 2604 | 83 | 215 | 1277 1996 JOURNAL OF INFLAMMATION 46(4):177-211 Zwingenberger K; Wnendt S Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations | 33 | 38 |
| 2605 | 0 | 0 | 18 1961 BRITISH MEDICAL JOURNAL 2(524):125-& [Anon] PURPURA ASSOCIATED WITH THALIDOMIDE | 0 | 0 |
| 2606 | 3 | 5 | 21 1961 BRITISH MEDICAL JOURNAL 2(525):876-& [Anon] THALIDOMIDE NEUROPATHY | 1 | 0 |
| 2607 | 0 | 0 | 46 1961 MEDICAL JOURNAL OF AUSTRALIA 1(23):868-& [Anon] THALIDOMIDE | 0 | 0 |
| 2608 | 0 | 0 | 60 1962 BRITISH MEDICAL JOURNAL (5283):1025-& [Anon] PERIPHERAL NEURITIS DUE TO THALIDOMIDE | 0 | 0 |
| 2609 | 2 | 4 | 61 1962 BRITISH MEDICAL JOURNAL (5290):1469-& [Anon] THALIDOMIDE (DISTAVAL) IN MEDICINE CUPBOARDS | 0 | 0 |
| 2610 | 0 | 0 | 63 1962 BRITISH MEDICAL JOURNAL (5298):175-& [Anon] PROSTHESES FOR INFANTS WITH DEFORMITIES CAUSED BY THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2611 | 0 | 0 | 73 1962 BRITISH MEDICAL JOURNAL (5307):785-& [Anon] PROPERTIES OF THALIDOMIDE | 0 | 0 |
| 2612 | 0 | 2 | 78 1962 BRITISH MEDICAL JOURNAL (5313):1176-& [Anon] CENSUS OF THALIDOMIDE BABIES | 0 | 0 |
| 2613 | 9 | 13 | 85 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(10):462-& [Anon] THALIDOMIDE AND CONGENITAL MALFORMATIONS | 1 | 0 |
| 2614 | 0 | 0 | 86 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(14):664-& [Anon] WITHDRAWAL OF THALIDOMIDE FROM MARKET | 0 | 0 |
| 2615 | 0 | 0 | 89 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 87(8):412-& [Anon] DISPOSAL OF SUPPLIES OF THALIDOMIDE | 0 | 0 |
| 2616 | 0 | 0 | 98 1962 ECONOMIST 204(8):711-712 [Anon] AFTER THALIDOMIDE | 0 | 0 |
| 2617 | 6 | 8 | 118 1962 LANCET 1(7224):307-& [Anon] THALIDOMIDE AND CONGENITAL MALFORMATIONS | 1 | 0 |
| 2618 | 0 | 1 | 138 1962 LANCET 2(7250):306-& [Anon] THALIDOMIDE BABIES | 0 | 0 |
| 2619 | 4 | 10 | 139 1962 LANCET 2(7251):336-& [Anon] THALIDOMIDE .2. | 0 | 0 |
| 2620 | 0 | 0 | 150 1962 LANCET 2(7262):931-& [Anon] CONGENITAL ABNORMALITIES DUE TO THALIDOMIDE | 1 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2621 | 0 | 0 | 152 1962 LANCET 2(7263):986-& [Anon] CONGENITAL ABNORMALITIES DUE TO THALIDOMIDE | 1 | 0 |
| 2622 | 5 | 35 | 153 1962 LANCET 2(7265):1095-& [Anon] THALIDOMIDE AND AFTER | 0 | 0 |
| 2623 | 0 | 0 | 162 1962 MEDICAL JOURNAL OF AUSTRALIA 2(7):267-& [Anon] THALIDOMIDE SITUATION | 0 | 0 |
| 2624 | 0 | 0 | 165 1962 MEDICAL JOURNAL OF AUSTRALIA 2(17):677-& [Anon] CARE OF THALIDOMIDE BABIES | 0 | 0 |
| 2625 | 1 | 14 | 176 1962 PUBLIC HEALTH REPORTS 77(11):946-946 [Anon] THALIDOMIDE | 0 | 0 |
| 2626 | 0 | 0 | 177 1962 ROYAL SOCIETY OF HEALTH JOURNAL 82(5):223-224 [Anon] THALIDOMIDE | 0 | 0 |
| 2627 | 0 | 0 | 195 1963 BRITISH MEDICAL JOURNAL (532):456-& [Anon] DERMATOGLYPHICS OF THALIDOMIDE BABIES | 0 | 0 |
| 2628 | 0 | 1 | 197 1963 BRITISH MEDICAL JOURNAL (533):664-& [Anon] SEX RATIO OF THALIDOMIDE BABIES | 0 | 0 |
| 2629 | 0 | 0 | 198 1963 BRITISH MEDICAL JOURNAL (534):1333-& [Anon] CONTINUING EFFECT OF THALIDOMIDE | 0 | 0 |
| 2630 | 0 | 0 | 203 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 88(9):488-& [Anon] REHABILITATION OF THALIDOMIDE-DEFORMED CHILDREN | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2631 | 0 | 0 | 277 1964 BRITISH MEDICAL JOURNAL 2(541):679-& [Anon] ONCOLYTIC PROPERTIES OF THALIDOMIDE | 0 | 0 |
| 2632 | 0 | 2 | 289 1964 LANCET 2(735):574-& [Anon] THALIDOMIDE | 0 | 0 |
| 2633 | 5 | 19 | 342 1965 LANCET 2(7421):1059-& [Anon] ANOTHER CHANCE FOR THALIDOMIDE | 7 | 0 |
| 2634 | 0 | 0 | 350 1965 POSTGRADUATE MEDICINE 38(4):A162-& [Anon] THALIDOMIDE LEGACY | 0 | 0 |
| 2635 | 0 | 0 | 364 1966 BRITISH MEDICAL JOURNAL 1(5479):92-& [Anon] THALIDOMIDE NEUROPATHY | 0 | 0 |
| 2636 | 1 | 1 | 365 1966 BRITISH MEDICAL JOURNAL 2(5510):400-& [Anon] THALIDOMIDE | 0 | 0 |
| 2637 | 0 | 1 | 378 1966 EYE EAR NOSE AND THROAT MONTHLY 45(4):74-& [Anon] THALIDOMIDE LEGACY | 0 | 0 |
| 2638 | 5 | 6 | 428 1967 BRITISH MEDICAL JOURNAL 4(5578):536-& [Anon] THALIDOMIDE IN LEPROSY | 0 | 0 |
| 2639 | 4 | 16 | 486 1969 LANCET 1(7597):713-& [Anon] THALIDOMIDE NEUROPATHY | 5 | 0 |
| 2640 | 0 | 0 | 556 1972 NATURE 240(5379):246-& [Anon] INSURING FOR THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2641 | 0 | 0 | 564 1973 CHEMICAL & ENGINEERING NEWS 51(4):11-12 [Anon] STIFFER DRUG LAWS IN WAKE OF THALIDOMIDE | 0 | 0 |
| 2642 | 5 | 9 | 614 1975 LANCET 1(7906):560-560 [Anon] POSTSCRIPT TO THALIDOMIDE | 0 | 0 |
| 2643 | 0 | 1 | 677 1978 LANCET 2(8085):385-385 [Anon] THALIDOMIDE | 0 | 0 |
| 2644 | 0 | 2 | 707 1979 MEDICINE SCIENCE AND THE LAW 19(4):272-272 [Anon] EUROPEAN COURT AND THALIDOMIDE | 0 | 0 |
| 2645 | 0 | 1 | 731 1980 REHABILITATION LITERATURE 41(1-2):36-38 [Anon] SUFFER THE CHILDREN - STORY OF THALIDOMIDE | 0 | 0 |
| 2646 | 1 | 1 | 758 1981 LANCET 2(8245):510-511 [Anon] THALIDOMIDE - 20 YEARS ON | 0 | 0 |
| 2647 | 0 | 5 | 858 1984 LANCET 2(8396):205-206 [Anon] DEBENDOX IS NOT THALIDOMIDE | 0 | 0 |
| 2648 | 15 | 15 | 899 1985 LANCET 2(8446):80-81 [Anon] THALIDOMIDE IN DERMATOLOGY AND LEPROSY | 7 | 0 |
| 2649 | 0 | 0 | 1180 1995 CHEMISTRY IN BRITAIN 31(10):760-760 [Anon] THALIDOMIDE REVIVAL | 0 | 0 |
| 2650 | 0 | 0 | 1189 1995 ENVIRONMENTAL HEALTH PERSPECTIVES 103(2):132-132 [Anon] RETHINKING THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2651 | 0 | 0 | 1190 1995 EUROPEAN CHEMICAL NEWS 63(1667):8-8 [Anon] GUINNESS TOPS UP THALIDOMIDE FUND | 0 | 0 |
| 2652 | 0 | 0 | 1227 1996 AIDS PATIENT CARE AND STDS 10(1):51-51 [Anon] Thalidomide effective in treating AIDS-related mouth ulcers | 0 | 0 |
| 2653 | 0 | 0 | 1228 1996 AIDS PATIENT CARE AND STDS 10(4):263-263 [Anon] Thalidomide trial for diarrhea | 0 | 0 |
| 2654 | 0 | 0 | 1299 1997 AIDS PATIENT CARE AND STDS 11(4):292-292 [Anon] Limited course of thalidomide effective in treating AIDS-related mouth ulcers | 0 | 0 |
| 2655 | 0 | 0 | 1300 1997 AIDS PATIENT CARE AND STDS 11(4):292-293 [Anon] Clinical sites initiated for thalidomide aphthous ulcer study | 0 | 0 |
| 2656 | 0 | 0 | 1301 1997 AIDS PATIENT CARE AND STDS 11(4):296-296 [Anon] Positive results reported for thalidomide in AIDS wasting | 0 | 0 |
| 2657 | 0 | 1 | 1307 1997 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 54(13):1485-1486 [Anon] Thalidomide heals HIV-related oral ulcers, but caution is required | 0 | 0 |
| 2658 | 0 | 0 | 1321 1997 CHEMISTRY & INDUSTRY (18):714-714 [Anon] Thalidomide for US | 0 | 0 |
| 2659 | 0 | 0 | 1334 1997 DRUG NEWS & PERSPECTIVES 10(8):506-506 [Anon] Celgene's thalidomide approvable for ENL | 0 | 0 |
| 2660 | 0 | 0 | 1335 1997 EUROPEAN CHEMICAL NEWS 68(1780):51-51 [Anon] Celgene - FDA approves thalidomide's use against ENL | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2661 | 0 | 0 | 1387 1997 SEARCH 28(8):239-239 [Anon] Inheriting thalidomide deformities | 0 | 0 |
| 2662 | 0 | 0 | 1393 1998 AIDS PATIENT CARE AND STDS 12(3):231-231 [Anon] Thalidomide studied in asymptomatic patients | 0 | 0 |
| 2663 | 0 | 0 | 1410 1998 BIOTECHNOLOGY LAW REPORT 17(3):361-362 [Anon] FDA grants orphan drug designation to thalidomide as treatment for primary brain cancers | 0 | 0 |
| 2664 | 0 | 0 | 1411 1998 BIOTECHNOLOGY LAW REPORT 17(5):596-597 [Anon] Notorious teratogen wins FDA approval for leprosy - Thalidomide will be most tightly regulated drug ever | 0 | 0 |
| 2665 | 0 | 0 | 1423 1998 CHEMISTRY & INDUSTRY (15):591-591 [Anon] Concern over US thalidomide approval | 1 | 0 |
| 2666 | 0 | 0 | 1464 1998 MEDICAL LETTER ON DRUGS AND THERAPEUTICS 40(1038):103-104 [Anon] Thalidomide | 1 | 0 |
| 2667 | 0 | 0 | 1468 1998 NATURE BIOTECHNOLOGY 16(8):695-695 [Anon] The problem with thalidomide's new incarnation | 0 | 0 |
| 2668 | 0 | 0 | 1590 1999 ONCOLOGY-NEW YORK 13(5):744-744 [Anon] Thalidomide shows promising results in patients with multiple myeloma | 0 | 0 |
| 2669 | 0 | 0 | 1687 2000 CA-A CANCER JOURNAL FOR CLINICIANS 50(1):3-3 [Anon] Once again, thalidomide in the news | 0 | 0 |
| 2670 | 0 | 0 | 1691 2000 CHEMISTRY & INDUSTRY (16):522-522 [Anon] Health - Thalidomide patents granted in US | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2671 | 0 | 0 | 1706 2000 DRUG NEWS & PERSPECTIVES 13(3):146-146 [Anon] Celgene's IMiDS and thalidomide show activity as COX-2 inhibitors | 1 | 0 |
| 2672 | 0 | 0 | 1770 2000 ONCOLOGY-NEW YORK 14(3):452-452 [Anon] Substantial activity of thalidomide in multiple myeloma, study shows | 0 | 0 |
| 2673 | 0 | 0 | 1771 2000 ONCOLOGY-NEW YORK 14(4):479-479 [Anon] Thalidomide active in advanced multiple myeloma | 0 | 0 |
| 2674 | 0 | 0 | 1772 2000 ONCOLOGY-NEW YORK 14(7):1081-1081 [Anon] Expanded data on thalidomide in advanced myeloma | 0 | 0 |
| 2675 | 0 | 0 | 1911 2001 CLINICAL LYMPHOMA 2(1):16-17 [Anon] Thalidomide shows promise in previously untreated and refractory multiple myeloma | 0 | 0 |
| 2676 | 16 | 47 | 1921 2001 DRUGS OF THE FUTURE 26(1):100-103 [Anon] Thalidomide - Synovir (R) - Thalomid (R) - Talizer (R) - Oncolytic treatment of IBD antiarthritic treatment of leprosy | 0 | 0 |
| 2677 | 1 | 1 | 1923 2001 EUROPEAN JOURNAL OF CANCER 37(16):1966-1966 [Anon] Thalidomide is back | 0 | 0 |
| 2678 | 0 | 2 | 1935 2001 HAEMATOLOGICA 86(4):348-348 [Anon] Thalidomide in the treatment of multiple myeloma | 0 | 0 |
| 2679 | 0 | 0 | 1988 2001 ONCOLOGY-NEW YORK 15(3):301-301 [Anon] Thalidomide analogs active against multiple myeloma | 0 | 0 |
| 2680 | 0 | 0 | 1989 2001 ONCOLOGY-NEW YORK 15(4):493-+ [Anon] Thalidomide studied in a variety of cancers and metabolic disorders | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2681 | 0 | 0 | 2154 2002 CHEMICAL & ENGINEERING NEWS 80(40):60-60 [Anon] Thalidomide and Frances Kelsey | 0 | 0 |
| 2682 | 14 | 22 | 2198 2002 HAEMATOLOGICA 87(4):345-346 [Anon] Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders | 0 | 0 |
| 2683 | 0 | 0 | 2337 2003 BIOTECHNOLOGY LAW REPORT 22(2):120-120 [Anon] Celgene, EntreMed agree to license for thalidomide analog - Companies will drop their infringement suits | 0 | 0 |
| 2684 | 0 | 0 | 2452 2003 EUROPEAN JOURNAL OF CANCER 39(7):854-854 [Anon] Thalidomide on trial | 0 | 0 |
| 2685 | 0 | 0 | 2503 2003 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |
Page 9: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22